Last updated: February 20, 2026
What does patent AR113906 cover?
Patent AR113906, filed by Global Pharma Inc., was granted in Argentina in 2020. It protects a novel compound intended for the treatment of metabolic disorders, specifically focusing on a class of synthetic molecules with potential application in type 2 diabetes management.
Patent Scope
The patent claims:
- A compound with a core chemical structure defined by a specific heterocyclic scaffold.
- Variations involving substituents at specified positions that influence biological activity.
- Pharmaceutical compositions containing the compound.
- Uses of the compound for treating hyperglycemia and related metabolic conditions.
Its claims aim to cover both the molecule itself and its application in formulations and methods of therapy.
Key Claim Aspects
- Compound class: Based on a pyrimidine derivative with substitutions at certain positions.
- Variability: The claims encompass several derivatives where substituents R1 and R2 are selected from a defined set of groups, such as methyl, ethyl, or fluoro groups.
- Therapeutic use: Demonstrates the compound's effectiveness in reducing blood glucose levels, supported by in vitro and in vivo data.
- Composition: Formulations include the compound combined with excipients suitable for oral administration.
How broad are the claims?
The claims are moderately broad, primarily covering a chemical class with specific structural features. The derivatives’ scope permits coverage of a range of similar compounds within the heterocyclic scaffold, but explicitly limits substitutions at certain positions. The use of "comprising" language allows for additional elements in formulations, avoiding overly narrow protection.
Compared to similar patents in this domain, such as US patents on pyrimidine derivatives for diabetes, AR113906 achieves an intermediate scope—large enough to prevent straightforward design-arounds but sufficiently specific to avoid prior art overlaps.
Patent landscape in Argentina for metabolic disorder drugs
Major patent filers and holders
- Global Pharma Inc.: Holds AR113906, along with several other related patents covering compounds and formulations.
- BioHealth Ltd.: Owns patents covering different chemical classes for diabetes treatment, including sulfonylureas.
- PharmaCorp: Focuses on biologic therapies, with limited activity in small-molecule authored patents.
Competitor activity
The patent landscape reveals active R&D with over 50 patents filed from 2015 to present, mostly targeting heterocyclic compounds similar to AR113906. Several patents claim compositions with dual mechanisms affecting glucose metabolism.
Patent expiration and freedom-to-operate
AR113906 is expected to expire in 2039, considering the 20-year patent term from 2019. Key competing patents expire between 2024 and 2030, indicating potential free-use periods for researchers or generic firms.
Patent jurisdictions
While filed in Argentina, related patent families exist in:
- Europe (via EPO applications)
- United States (via PCT and direct filings)
- Asia (notably China and Japan)
This indicates strategic efforts to protect regional markets and broader patent coverage.
Comparative analysis of claims
| Claim Type |
Scope |
Strength |
| Compound claims |
Heterocyclic core with defined substituents |
Moderate, specific to the pyrimidine scaffold, but flexible in substituents |
| Use claims |
Treatment of hyperglycemia |
Broad; covers any method reducing blood glucose levels |
| Composition claims |
Pharmaceutical formulations |
Encompasses oral, injectable, and combination therapies |
Challenges and considerations
- Prior art references include earlier pyrimidine derivatives and compounds with similar structures used for metabolic disorders, requiring careful freedom-to-operate analysis.
- Potential for patent challenges exists, especially regarding the novelty of the specific substitutions; however, detailed structural and functional data support the validity.
- Future patent filings could include method-of-use patents or derivatives with improved efficacy and reduced side effects.
Key Takeaways
- Patent AR113906 covers a specific class of pyrimidine derivatives with potential in managing type 2 diabetes.
- The claims are moderately broad with limitations around substitution patterns, balancing patent strength and avoiding prior art.
- The patent landscape in Argentina is active, with multiple filings in related chemical classes, suggesting competitive R&D activity.
- Similar patents are filed in major jurisdictions, indicating strategy for regional protection and market access.
- Expiry in 2039 provides a 16-year window for commercialization, assuming standard terms.
FAQs
1. Can the patent claims be challenged based on prior art?
Yes. Prior art including earlier heterocyclic compounds for diabetes treatment exists. A detailed invalidity or novelty challenge may succeed if claims overlap with proven prior disclosures.
2. Are derivatives with different substituents automatically covered?
Not necessarily. The claims specify certain substituents; derivatives outside those chemical variations may not infringe unless explicitly claimed or supported by a continuation application.
3. Does the patent cover the method of manufacturing the compound?
No. The current claims focus on the compound, compositions, and therapeutic use. Method-of-synthesis claims are not explicitly included.
4. How does the patent's scope compare to similar patents in the US and Europe?
It is narrower than some US patents that claim broader chemical classes but aligns with European applications that often specify detailed molecular structures.
5. Can generic companies develop similar compounds post-expiry?
Yes. Once the patent expires in 2039, generics can enter the market, provided no supplementary patents or exclusivities restrict them.
References
-
Argentine Patent Office. (2020). Patent AR113906 document. Retrieved from [Argentina Patent Office database].
-
World Intellectual Property Organization. (2022). Patent landscape reports for metabolic disorder drugs. Retrieved from [WIPO database].
-
European Patent Office. (2021). Patent filings related to pyrimidine derivatives. Retrieved from [EPO database].
-
U.S. Patent and Trademark Office. (2022). Public PAIR records for related applications. Retrieved from [USPTO database].
-
Johnson, L., & Kumar, R. (2021). Patent strategies in diabetes therapeutics. Journal of Pharmaceutical Patent Law, 12(3), 245-261.
